AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 291 min read$BIVI

KIM JOANNE WENDY purchased $5K of BIVI

KIM JOANNE WENDY (Chief Financial Officer) purchased 2,500 shares of BIOVIE INC. (BIVI) at $2.18 on 2026-08-28.

Original reporting
SEC EDGAR · KIM JOANNE WENDY
Published Aug 29, 2026, 12:58 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 29, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BIVI
Neutral
low confidence
Mentioned
$BIVI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BIVINeutralLow
01

Why it matters

The CFO's purchase is a routine insider trade with limited material impact.

02

Market read

Minor insider purchase; unlikely to affect broader market.

03

What to watch

Potential upcoming corporate actions not disclosed in the filing.

Relevance 4/10Novelty 3/10Timing: post‑market filing on 2026‑08‑28

Background

Form 4 disclosures are primary sources for insider transactions.

Company-level read

Ticker impact

$BIVINeutralLow confidence
Context

CFO Kim Joanne Wendy bought 2,500 shares of BIOVIE Inc. for $5,450 in a Form 4 filing.

Expected impact

Minimal price movement expected.

Evidence & confidence

Purchase size is modest ($5k) for a micro‑cap; unlikely to move the stock significantly.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could be a subtle confidence signal despite small size.

Key entities

  • Company
    BIOVIE Inc.

    Biotech firm listed under ticker BIVI.

  • Insider
    Kim Joanne Wendy

    Chief Financial Officer of BIOVIE Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BIVI insider trading history →

Related articles

AUG 7
$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

yahoo.com4 min
AUG 6
$BIVIMedAI 8/10

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI) reported positive Phase 2 SUNRISE-PD results for its Parkinson's candidate bezisterim. The drug met prespecified endpoints in early-stage, untreated patients, improving blood inflammatory markers and EPNIC-15 versus placebo. Benefits were strongest in patients with higher baseline platelet counts. Safety was similar to placebo, with 39.3% adverse events vs 51.7%.

proactiveinvestors.com4 min
MAY 30
$BIVIMedAI 9/10

BioVie: Long COVID trial fully enrolled – ICYMI

BioVie Inc (NASDAQ:BIVI) said its Phase 2 long COVID trial of bezisterim is fully enrolled, with more than 200 patients randomized to placebo or bezisterim. CEO Cuong Do said the study includes sites such as Yale, Mount Sinai, Mayo Clinic and Stanford, targeting symptoms like brain fog, malaise and fatigue. Top-line results are expected by late October or as early as September; the company plans FDA discussions on accelerated approval or EUA if data support benefit-risk.

proactiveinvestors.com4 min